Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.46 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA3 | P07451 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.39 |
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1225879 | 1.00 | GSK3B (0.46) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL13174142 | 0.81 | CA12 (0.44) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL11980418 | 0.81 | CA12 (0.44) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL28239877 | 0.81 | CA12 (0.44) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL4084185 | 0.79 | LOXL2 (0.48) | CA2CA12CA3CA6CA9 | |
| SCHEMBL11980400 | 0.79 | CA12 (0.43) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL18245963 | 0.79 | LMNA (0.54) | CA2CA12CA3CA6CA9 | |
| SCHEMBL7105483 | 0.79 | CA12 (0.43) | GSK3BCA2CA12CA3CA6 | |
| SCHEMBL2249403 | 0.79 | LMNA (0.54) | CA2CA12CA3CA6CA9 | |
| SCHEMBL3409357 | 0.79 | TAAR1 (0.57) | CA2CA12CA3CA6CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-60139658-A | — | — | None | — | — | JP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| CN-102548989-A | Sphingosine-1-phosphate receptor agonists | BRISTOL MYERS SQUIBB CO | 2012-07-04 | — | — | CN | disclosed |
| EP-2462139-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | Bristol-Myers Squibb Company (US) | 2012-06-13 | — | — | EP | disclosed |
| US-8153410-B2 | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules | FOX CHASE CANCER CENTER (US) | 2012-04-10 | — | — | US | disclosed |
| US-8153410-B2 | Alternate morpheein forms of allosteric proteins as a target for the development of bioactive molecules | FOX CHASE CANCER CENTER (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | FOX CHASE CANCER CENTER (US) | 2009-02-19 | — | — | US | disclosed |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | FOX CHASE CANCER CENTER (US) | 2009-02-19 | — | — | US | disclosed |
| EP-0792936-B1 | Process for the preparation of optically active 2-halo-1-(substituted phenyl) ethanol | MITSUBISHI CHEM CORP (JP) | 2003-01-29 | — | — | EP | disclosed |
| US-5841001-A | ALLOWING 2-HALO-1-(SUBSTITUTED PHENYL)ETHANOL TO CONTACT ENZYME STEREOSELECTIVELY CATALYZING ESTER INTERCHANGE IN PRESENCE OF CARBOXYLIC ANHYDRIDE | MITSUBISHI CHEMICAL CORPORATION (JP) | 1998-11-24 | — | — | US | disclosed |
| EP-0792936-A2 | Process for the preparation of optically active 2-halo-1-(substituted phenyl) ethanol | Mitsubishi Chemical Corporation (JP) | 1997-09-03 | — | — | EP | disclosed |
| JP-S60139658-A | ETHANOLAMINE DERIVATIVE | TOOA EIYOO KK | 1985-07-24 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | GSK3B 2835/4885CA2 3237/4885CA12 4822/4885 |
| US-20090048324-A1 | ALTERNATE MORPHEEIN FORMS OF ALLOSTERIC PROTEINS AS A TARGET FOR THE DEVELOPMENT OF BIOACTIVE MOLECULES | BMP2, BMP1, MYOF | GSK3B 1746/4885CA2 2545/4885CA12 4203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.